1. 27/08/2016 Destination Kenya: A new horizon for Conducting Clinical Research ­ Clinical Trials Arena
http://www.clinicaltrialsarena.com/news/operations/destination­kenya­a­new­horizon­for­conducting­clinical­research­4982984 1/2
Operations
Destination Kenya: A new horizon for
Conducting Clinical Research
12:16, August 18 2016
Gaurav Puppalwar, Head Medical A儞Ⴈairs – Emerging Markets,
Wockhardt Limited, explores Kenya as a developing hub for clinical
research in Africa
Africa is one of the world’s fastest-growing economic regions. What’s more, the continent is emerging as an important
target for clinical research, although developing countries are usually under-represented due to the lack of
commercial viability and trained researchers. With the descent of traditional pharmaceutical markets, Africa is one
such destination which has developed interest for most pharmaceutical companies of all sizes.
One of the regions in Africa that is making remarkable progress with investments in institutions, integration, and
infrastructure is the East African Community (EAC). The EAC is a regional intergovernmental organisation of the
Republics of Kenya, Uganda, Tanzania, Burundi and Rwanda with its headquarters in Arusha, Tanzania. Kenya is
considered the reference standard being the largest economy in the region and is much more dynamic than those of
other member countries. This makes Kenya the most sought after destination for generating data in the African
population as far as ease and standards of conducting clinical research are concerned.
The National Council for Science and Technology (NCST) oversees and coordinates all research activities in Kenya and
functions as the advisory to government in all matters related to research. The Expert Committee on Clinical Trials
(ECCT), organized by the drug regulatory body – Pharmacy and Poisons Board (PPB), has developed guidelines to steer
through the clinical trial authorization process in Kenya. Approval from the ECCT is not required for drugs already
registered in Kenya with approval from the ethical review committee of each respective institution suᅚ�cient.
The unique framework of the clinical research approval system in Kenya is such that a foreign sponsor has to be
aᅚ�liated with either of the following institutes:
Kenya Medical Research Institute (KEMRI),
Kenyatta National Hospital (KNH),
Eldoret Referral Hospital, and/or Aga Khan Hospital
KEMRI, KNH and Eldoret referral hospital are the national functionaries, while Aga Khan Hospital is a not-for-pro᥄t
private chain of hospitals. This is the testimony to the prominence of private as well as public sector in health care
infrastructure.
There is a distinct advantage in conducting clinical research in aᅚ�liation with KEMRI. KEMRI is a national body
dedicated for research activities in Kenya. It has its centres present across Kenya. It is much easier for a government
organization, like KEMRI, to get connected with not only other government health care bodies but also associate with
private health institutions for conducting any multisite/multicentric study in Kenya. The regional collaboration of
KEMRI with various research facilities in neighbouring countries facilitates for faster coordination in multi-country trials.
Internationally, KEMRI also collaborates with various organisations, such as:
The World Health Organization (WHO),
The Japan International Cooperation Agency (JICA),
US Centers for Disease Control and Prevention (CDC),
The Walter Reed Army Institute of Medical Research,
Welcome Trust-UK,
United States Agency for International Development (USAID),
British Medical Research Council,
More
More
Axiom Real-Time Metrics
Know More. Know it Sooner. Act Faster.
PCI Clinical Services
Excellence in Clinical Trial Services
Outsourcing from Molecule to Market
ACRO (African Clinical Research
Organisation)
ACRO (African Clinical Research
Organisation) is the ᥄rst South African, full-
service, black economic empowerment,
contract research organisation...
Novotech
Established in 1996, Novotech is the largest
independent Australia-based CRO.
Getting your Trial Drugs from
X to Y
Embed View on Twitter
Tweets by @ArenaClinical
26 Aug
26 Aug
26 Aug
#FollowFriday @LillyTrials @alsadvocacy top
Influencers this week! Have a great weekend :)
>> Want this ? commun.it/get­more­follo…
#Lookingback ­ Welcome IRT to your Clinical
Trials ow.ly/fEwG303BEkg
#Lookingback ­ Outsourcing practice a major
barrier to realizing promise of strategic alliances
ow.ly/uk7J303Bp4f #HappyBirthdayCTA
The Pros and Cons of Academic Partnerships in
Clinical Research ow.ly/l2TA503Re0g
ClinicalTrialsArena
@ArenaClinical
ClinicalTrialsArena
@ArenaClinical
ClinicalTrialsArena
@ArenaClinical
ClinicalTrialsArena
@ArenaClinical
Operations Supplier Directory
Latest Tweets
Operations Supply Chain Data Outsourcing Finance Technology Medical Devices Regulations Resources Events Suppliers
Enter your search term...Search

2. 27/08/2016 Destination Kenya: A new horizon for Conducting Clinical Research ­ Clinical Trials Arena
http://www.clinicaltrialsarena.com/news/operations/destination­kenya­a­new­horizon­for­conducting­clinical­research­4982984 2/2
Share:
British Medical Research Council,
Royal Tropical Institute, Amsterdam, and
World Association of Industrial and Technological Research Organizations (WAITRO) among others
Various global projects on the control of tuberculosis, HIV/AIDS and malaria have been driven in alliance with KEMRI.
Conducting Clinical Research in Kenya: the SWOT
Analysis
Strengths
Rapid economic growth with advances in health care infrastructure is the crucial factor attracting much of the research
activity in Kenya. Political stability and reformative decisions are the backbone for the current state of Kenya.
Additionally, the country provides a high burden of disease and a large treatment naïve population. Kenya is also an
Anglophone (English speaking) country making communications coherent for foreign sponsors, researchers and study
site personnel.
The clinical research operating cost is economical in Kenya compared to developed pharma markets in the West. The
research cost may be relatively lower compared to some of Kenya’s neighbouring countries. This can be attributed to
fewer committees that need to be approached for project approvals, meaning fewer submission fees that need to be
levied, but more importantly time saved.
Weaknesses
Bureaucratic and non-transparent information from governmental agencies, including PPB and KEMRI can bring down
the credits for research undertakings in Kenya.
The complicated review mechanisms with multi-layered committees, especially with KEMRI, for assessment of a
proposal prolong the approval process. The uni᥄cation of both the scienti᥄c steering committee as well as the ethical
review committee is under process at KEMRI.
Furthermore, there is limited availability of trained medical and health care sta儞Ⴈ. Higher attrition and non-trained
research sta儞Ⴈ necessitates frequent training and refresher sessions during the study conduct. Poor public transport
facilities also hinder the subject follow-up visits and increase the study drop-out rates. Public transport is also
detrimental to the visits of a ᥄eld worker associated with the study.
Opportunities
From the pharmaceutical company’s perspective, the untapped potential of developing research facilities in Kenya can
bring long-term paybacks with respect to collaboration, gaining faith of patient pool and researchers, and opportunity
to become foundation-setters for the system.
The stronghold image of Kenya amongst the EAC members, as well as the African continent in general, needs to be
continued and maintained by the government, the people, and researchers to reinforce the entry of more and more
pharmaceutical companies to this region.
Threats
Nevertheless, corruption is often cited as a key factor thwarting the humanitarian development in the country and a
curse a儞Ⴈecting public health services and development of key infrastructure. Even though the medical fraternity is less
involved in this kind of practices and the present government is taking e儞Ⴈorts in this area, there is a need for concrete
measures to be undertaken to overcome this apprehension.
Some unfortunate incidents along with the presence of counterfeit medications in the market have generated mistrust
and brought down the image of pharmaceutical industry. Recently many people have raised concerns owing to the
undue advantage of poverty and illiteracy being taken by researchers and pharmaceutical sponsors. The same can be
tackled by conducting Good Clinical Practices (GCP) compliant research that are relevant to local realities and
contexts, ensuring sound scienti᥄c and ethical standards. Compliance with these standards will provide the public with
assurance that the rights, safety, and well-being of the trial participants are protected.
Kenya is capable of developing into research capital, especially in sub-Saharan Africa. Positive moves from
pharmaceutical companies, clinical researchers, and governmental bodies can bring revolutionary change in Kenya.
Kenya can be considered an important destination not only for wild-life adventures but also for research and clinical
data generation activity to market the pharmaceutical products in Africa.
PHOTO CREDIT: Nicolas Raymond via FreeStock.ca
| About Us . Advisory Board . Contact Us
© Clinical Trials Arena 2015 | Part of Progressive Digital Media Group Plc. Home Privacy Terms and conditions Contact us Site map